Morphic's oral UC drug shows promise in achieving primary endpoint and spurs Entyvio comparisons.

Morphic Therapeutic has announced positive mid-stage data for its oral med MORF-057 in the ulcerative colitis R&D space, meeting the study's primary goal by showing a statistically significant 6.4-point reduction on a score known as the Robarts Histopathology Index. The biotech hopes it will be an easier option for patients than Takeda's intravenous Entyvio. Meanwhile, Biogen's drug, tofersen, has been granted accelerated approval by the FDA for a rare type of amyotrophic lateral sclerosis, or ALS, giving a small subset of patients a new and much-needed treatment option.